Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (314)	3/26/1999 5:17:00 AM
From: Peter J.	Respond to of 550

easynet.on.ca Have a nice day ...

To: Miljenko Zuanic who wrote (314)	3/26/1999 7:04:00 AM
From: Peter J.	Respond to of 550

easynet.ca

To: Miljenko Zuanic who wrote (314)	3/26/1999 7:18:00 AM
From: Peter J.	Respond to of 550

easynet.ca

To: Miljenko Zuanic who wrote (314)	3/26/1999 12:26:00 PM
From: gao seng	Read Replies (1) \| Respond to of 550

What is your point? SUGN's product has already been shown to be non-toxic ( the purpose of Phase I trials). Thalidomide has nothing to do with SUGN. Unless you have just crawled out from under a rock, you should already know that Thalidomide is toxic. More funding means (to me) a greater chance of success and an increase in confidence of the company. Why don't you just ask "Why is SUGN concentrating on colon cancer instead of all cancer" This is not an attack on you, but I do think you should defend your attack on sugn with some valid reasoning.